TRIUMPH-2: Retatrutide Phase 3 trial (NCT05929079)
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 1,152
- actual
- Start
- 11 Jul 2023 (actual)
- Primary completion
- 16 Jun 2026 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Retatrutide Dose 1 | Experimental | Drug: Retatrutide | Participants will receive retatrutide subcutaneously (SC). |
| Retatrutide Dose 2 | Experimental | Drug: Retatrutide | Participants will receive retatrutide SC. |
| Retatrutide Dose 3 | Experimental | Drug: Retatrutide | Participants will receive retatrutide SC. |
| Placebo | Placebo comparator | Drug: Placebo | Participants will receive placebo. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 80 |
| Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset | Baseline, Week 80 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change from Baseline in Body Mass Index (BMI) | Baseline, Week 80 |
| Change from Baseline in Waist Circumference | Baseline, Week 80 |
| Change from Baseline in Systolic Blood Pressure (SBP) | Baseline, Week 80 |
| Change from Baseline in Diastolic Blood Pressure (DBP) | Baseline, Week 80 |
| Percent Change from Baseline in Total Cholesterol | Baseline, Week 80 |
| Percent Change from Baseline in Triglycerides | Baseline, Week 80 |
| Change from Baseline in Hemoglobin (A1c) HbA1c % | Baseline, Week 80 |
| Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score | Baseline, Week 80 |
| Change from Baseline in Fasting Glucose | Baseline, Week 80 |
| Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) | Baseline through Week 80 |
| Percent Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset | Baseline, Week 80 |
| A Hierarchical Combination of Functional Outcomes of Sleep Questionnaire (FOSQ) 10 score, FOSQ Vigilance Domain Score, and FOSQ Activity Level Domain Score for GSA2 Subset | Baseline to Week 80 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
TRIUMPH-2 in adults with obesity and type 2 diabetes
Participants were randomised 1:1:1:1 to placebo or retatrutide 4, 9 or 12 mg, with week 80 bodyweight change as the primary endpoint for 9 and 12 mg.[2]
Mean bodyweight change was -11.9% on 4 mg, -16.8% on 9 mg and -18.8% on 12 mg, against -5.1% on placebo.[2]
Permanent discontinuation due to adverse events or death was 12% on 9 mg and 8% on 12 mg, compared with 4% on 4 mg and 5% on placebo.[2]
Diarrhoea occurred in 27%, 34% and 34% of the three retatrutide groups against 13% on placebo.[2]
Sources
- 1A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled TrialClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
Found an error? Report a correction.